Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tifcemalimab and Toripalimab with Chemotherapy for Limited-Stage SCLC
NCT06256237Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Started Apr 2024; status: recruiting.
02
Drugs
tifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06256237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256237.